Deal with Biovitrum Worth $130M Up Front
Amgen Sheds Three Products to Focus on 'Bigger Picture'
A day before the release of highly anticipated detailed risk-benefit data for osteoporosis drug denosumab, Amgen Inc. said it was divesting three marketed products to Swedish specialty pharma firm Biovitrum AB in exchange for $130 million up front, plus potential sales milestones and royalties down the road. (BioWorld Today)